Last reviewed · How we verify
Sevoflurane, Sufentanil
Sevoflurane, Sufentanil is a General anesthetic, Opioid analgesic Small molecule drug developed by University of Saskatchewan. It is currently in Phase 3 development for General anesthesia, Pain management. Also known as: Opioid-containing maintenance medications.
Sevoflurane acts as a general anesthetic by modulating the activity of GABA_A receptors, while Sufentanil is a potent opioid analgesic that binds to mu-opioid receptors.
Sevoflurane acts as a general anesthetic by modulating the activity of GABA_A receptors, while Sufentanil is a potent opioid analgesic that binds to mu-opioid receptors. Used for General anesthesia, Pain management.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sevoflurane, Sufentanil |
|---|---|
| Also known as | Opioid-containing maintenance medications |
| Sponsor | University of Saskatchewan |
| Drug class | General anesthetic, Opioid analgesic |
| Target | GABA_A receptor, Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Sevoflurane's mechanism of action involves enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at GABA_A receptors, leading to sedative and anesthetic effects. Sufentanil, on the other hand, binds to mu-opioid receptors, which are involved in pain modulation, leading to analgesic effects.
Approved indications
- General anesthesia
- Pain management
Common side effects
- Respiratory depression
- Nausea and vomiting
- Hypotension
- Bradycardia
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Anesthesia sTrategy foR Organ Procurement In braiN dEath (PHASE3)
- Differences in Speed of Recovery From Anesthesia for Intraoral Surgery (NA)
- Effectiveness of Dexmedetomidine Versus Sufentanil on Cerebral Oxygen Saturation in Patients With Traumatic Brain Injury (NA)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty (NA)
- Perioperative GDNF as a Predictive Factor for Postoperative Delirium and Adverse Neurological Outcomes in Pediatric Surgery (NA)
- Spinal Versus General Anesthesia on Postoperative Pulmonary Complications (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevoflurane, Sufentanil CI brief — competitive landscape report
- Sevoflurane, Sufentanil updates RSS · CI watch RSS
- University of Saskatchewan portfolio CI
Frequently asked questions about Sevoflurane, Sufentanil
What is Sevoflurane, Sufentanil?
How does Sevoflurane, Sufentanil work?
What is Sevoflurane, Sufentanil used for?
Who makes Sevoflurane, Sufentanil?
Is Sevoflurane, Sufentanil also known as anything else?
What drug class is Sevoflurane, Sufentanil in?
What development phase is Sevoflurane, Sufentanil in?
What are the side effects of Sevoflurane, Sufentanil?
What does Sevoflurane, Sufentanil target?
Related
- Drug class: All General anesthetic, Opioid analgesic drugs
- Target: All drugs targeting GABA_A receptor, Mu-opioid receptor
- Manufacturer: University of Saskatchewan — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for General anesthesia
- Indication: Drugs for Pain management
- Also known as: Opioid-containing maintenance medications
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing